TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05338034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPG1860
Description: The dosage form for clinical research is a dry-filled capsule for oral administration manufactured as strengths of 3 mg, 5 mg, and 8 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPG1860
Description: The dosage form for clinical research is a dry-filled capsule for oral administration manufactured as strengths of 3 mg, 5 mg, and 8 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPG1860
Description: The dosage form for clinical research is a dry-filled capsule for oral administration manufactured as strengths of 3 mg, 5 mg, and 8 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule
Study: NCT04814121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suxiao Jiuxin Pills
Description: Suxiao Jiuxin Pills consists Rhizoma Ligustici (Chuan xiong) and Borneolum (Bing pian).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The placebo of Suxiao Jiuxin Pills
Description: The placebo of Suxiao Jiuxin Pills is similar to Suxiao Jiuxin Pills in appearance, smell, and taste.
Study: NCT06566027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skeletal, dental, soft tissue index changes in Activator group
Description: After being interviewed and provided by a doctor with two kinds of appliances (Activator and EF class II standard) for treating class II malocclusion, the patients choose their appliance. The patients were separated into two groups (30 in each). Group 1 was treated with an Activator appliance (Activator group), whereas Group 2 was treated with an EF class II standard appliance (EF line group)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skeletal, dental, soft tissue index changes in Activator group
Description: After being interviewed and provided by a doctor with two kinds of appliances (Activator and EF class II standard) for treating class II malocclusion, the patients choose their appliance. The patients were separated into two groups (30 in each). Group 1 was treated with an Activator appliance (Activator group), whereas Group 2 was treated with an EF class II standard appliance (EF line group)
Study: NCT06236919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR cognitive training
Description: The VR cognitive training group will engage in a subset of six games designed to target specific cognitive functions one game will target cognitive flexibility, requiring participants to switch between different tasks and problem-solving strategies quickly. Another game will focus on planning, asking participants to make a series of decisions to achieve a particular goal. Additionally, the Enhance VR group will also engage in games that target reappraisal strategies, working memory, divided and sustained attention, impulsivity, and processing speed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VR nature exposure relaxation
Description: The control group will be immersed in ten different nature-based VR environments (e.g., forests, lakes, beaches, etc.), where they will tailor its content and perform relaxation exercises (deep breathing techniques).
Study: NCT05789836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing care
Description: Involving the mother in nursing care
Study: NCT05501106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Improvement strategies
Description: Integrated improvement strategies include postpartum hemorrhage risk screening, hierarchical management and preparedness, postpartum hemorrhage rescue recording, and review of postpartum hemorrhage cases.~1. A checklist (named as Risk Assessment and Preparedness for Postpartum Hemorrhage (Traffic Light in Delivery Room)) will be used in each virginal delivery to help obstetric staff and teams identify risk factors after admission, before and during labor, and improve the adherence to all known best practices.~2. The Postpartum Hemorrhage Rescue Format will be asked to be used in each postpartum hemorrhage rescue to record the rescue process.~3. Each case of postpartum hemorrhage exceeding 1000 ml will be reviewed. We will convene a QI Panel and a Task Force to assist the hospitals in postpartum hemorrhage case review and quality improvement strategy development.
Study: NCT06077188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gum group
Description: Group chewing gum with xylitol
Study: NCT05527665

Intervention type: PROCEDURE
Intervention: Midurethral sling surgery
Description: This treatment consists of the placement of a sub-urethral sling, usually made of polypropylene, in order to support the urethra during efforts and thus to avoid leaks linked to its hyper mobility. This is a frequent and rapid surgery, which is performed on an outpatient basis. The sling is placed under the patient's urethra with the help of an awl.
Study: NCT05266417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS-GSH
Description: Intranasal INS-GSH Twice Daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebos
Description: Intranasal Matched Placebos Twice Daily
Study: NCT06721975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thulio pulsed Thulium:YAG (p-Tm:YAG)
Description: A new laser system developed by Dornier, the Thulio pulsed Thulium:YAG (p-Tm:YAG ) is beginning to be studied in vitro and in vivo. Dornier Thulio p-Tm:YAG may represent an attractive new laser platform, with comparable properties to TFL including decreased retropulsion, smaller dust, and improved ablation efficiency relative to Ho:YAG.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thulium Laser Fiber (TFL)
Description: The thulium fiber laser (TFL) has demonstrated effectiveness in this procedure
Study: NCT06720649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isokinetic test
Description: Bilateral strength will be measured using a Contrex ® dynamometer equipped with an exercise table. Each subject will perform isokinetic tests of the right and left knee extensors and flexors. Subjects will be stabilized by straps during testing and the joint rotation axis will be aligned with the input shaft of the dynamometer.
Study: NCT02245945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TFV 1% vaginal gel
Description: Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HEC Placebo Gel
Description: Placebo gel contains hydroxyethylcellulose (HEC) as the gel thickener, purified water, sodium chloride, sorbic acid and sodium hydroxide. The gel is isotonic and formulated at a pH of 4.4. Each pre-filled applicator will contain approximately 4 mL of placebo gel for delivery.
Study: NCT05932979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: L-arginine 2-amino-5-guanidino-pentanoic acid is a proteinogenic amino acid that is a natural constituent of the protein diet.
Study: NCT06720649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ballistic test
Description: ballistic squat jumps performed in the supine position on a frictionless sled at a resistance between 0% of body weight (BW)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: K-STARTS test
Description: The K-STARTS (Knee Health Athletic Return To Sport) test brings together a set of 7 tests validated in the scientific literature to assess the control and neuromuscular capacities of the lower limb when performing dynamic movements as well as apprehension when resuming activity.~Test in 30 minutes with physical exercises and questionnaire.
Study: NCT05932979

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starch
Study: NCT04877405

Intervention type: OTHER
Intervention: No intervention
Description: This observational study is not focused on therapeutic intervention
Study: NCT06270953

Intervention type: DEVICE
Intervention: Dozee Pro NX
Description: Dozee Pro NX to measure Heart Rate, Respiratory Rate, SPO2 and movements
Study: NCT06720649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: KOOS (Knee Injury and Osteoarthritis Outcome Score) Questionnaire
Study: NCT06721793

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carbohydrate electrolyte drink
Description: 2% carbohydrate solution with 1,020 mg/L of Sodium

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: no-sugar electrolyte drink
Description: 1% carbohydrate solution with 1,060 mg/L of Sodium

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeinated Carbohydrate and electrolyte drink
Description: 2% carbohydrate solution with 1,000 mg/L of Sodium, and 200mg/L caffeine
Study: NCT05880303

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy
Description: Oral Hygiene education, scaling and root surface debridement at baseline and 3 months
Study: NCT05838768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRO761
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRO761
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRO761
Description: Tablet

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Concentrate for solution for infusion
Study: NCT05205291

Intervention type: DRUG
Intervention: Lipopolysaccharide
Description: All participants will receive one dose of Lipopolysaccharide (1ng/Kg) after the first PET/MR scan with \[11C\]PBR28 and four hours before the second PET/MR scan with \[11C\]PBR28.

Intervention type: DRUG
Intervention: Lipopolysaccharide
Description: All participants will receive one dose of Lipopolysaccharide (1ng/Kg) after the first PET/MR scan with \[11C\]PBR28 and four hours before the second PET/MR scan with \[11C\]PBR28.

Intervention type: RADIATION
Intervention: PET/MR with [11C]PBR28
Description: A PET/MR scan using the tracer \[11C\]PBR28 will be performed to all participants before and four hours after the administration of LPS

Intervention type: RADIATION
Intervention: PET/MR with [11C]PBR28
Description: A PET/MR scan using the tracer \[11C\]PBR28 will be performed to all participants before and four hours after the administration of LPS
Study: NCT04587050

Intervention type: DIAGNOSTIC_TEST
Intervention: Human papillomavirus testing
Description: HPV test from cervical sample using Cepheid GeneXpert HPV

Intervention type: DIAGNOSTIC_TEST
Intervention: Cervical cytology
Description: Cervical cytology

Intervention type: DIAGNOSTIC_TEST
Intervention: HPV serology
Description: HPV type specific serology (16/18) using ELISA from serum samples

Intervention type: DIAGNOSTIC_TEST
Intervention: HPV serology
Description: HPV type specific serology (16/18) using ELISA from serum samples
Study: NCT05552963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-Channel Irreversible Electroporation (IRE) Generator
Description: The multi-channel IRE Generator is intended for use during cardiac Pulsed Field Ablation (PFA) therapy. This device is used in conjunction with a compatible ablation catheter to create a closed electrical circuit capable of delivering pulsed electrical field energy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-Channel Circular IRE Catheter
Description: The multi-channel circular IRE Catheter is indicated for use in catheter-based cardiac electrophysiological mapping (stimulating and recording) and when used with an IRE Generator, for cardiac ablation.
Study: NCT05639296

Intervention type: OTHER
Intervention: Discovery learning (DL)
Description: DL makes the trainee practice before giving them instruction, Do-Then-Tell, thereby promoting their ability to use and build upon their existing knowledge.
Study: NCT04529941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device Implant with Active Treatment
Description: ScNS at 3.5mA output for 2 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Device Implant without Active Treatment
Description: No device output for 2 weeks
Study: NCT05534399

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Intra-vesical BoNTA injections
Description: Intra-vesical BoNTA injections will be performed according to the protocol currently applied by the department.~They will be performed in the operating room or in the outpatient clinic under strict asepsis, including the wearing of sterile gloves by the surgeon associated with an antiseptic brushing of the patient and the establishment of sterile fields.~A rigid or a flexible cystoscope will be used.~After the introduction of the cystoscope under visual control, complete bladder emptying will be performed. The bladder will be filled again, slowly and at low pressure to allow the bladder mucosa to expand.~BoNTA (BOTOX® 200 U) will be diluted as follows: BOTOX® 200 U: in 30 mL of saline solution~The solution obtained will be injected all along the bladder wall, sparing the trigone in 20 (BOTOX® 200 U) points using a Bonee®-type needle.~A complete bladder emptying will be performed at the end of the procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-vesical BoNTA injections
Description: Intra-vesical BoNTA injections will be performed according to the protocol currently applied by the department.~They will be performed in the operating room or in the outpatient clinic under strict asepsis, including the wearing of sterile gloves by the surgeon associated with an antiseptic brushing of the patient and the establishment of sterile fields.~A rigid or a flexible cystoscope will be used.~After the introduction of the cystoscope under visual control, complete bladder emptying will be performed. The bladder will be filled again, slowly and at low pressure to allow the bladder mucosa to expand.~BoNTA (BOTOX® 200 U) will be diluted as follows: BOTOX® 200 U: in 30 mL of saline solution~The solution obtained will be injected all along the bladder wall, sparing the trigone in 20 (BOTOX® 200 U) points using a Bonee®-type needle.~A complete bladder emptying will be performed at the end of the procedure.
Study: NCT06721793

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water (Placebo)
Description: flavored water with non-caloric, non-sodium-containing sweetner
Study: NCT06721247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium
Description: oral intake of magnesium for asthmatic patients with dose 200 mg per day for one year in addition to usual asthmatic treatment according to GINA guidelines 2024

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ICS+LABA
Description: inhaled corticosteroids with long acting Beta 2 agonist are given to control group patients twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICS+LABA
Description: inhaled corticosteroids with long acting Beta 2 agonist are given to control group patients twice daily
Study: NCT06720129

Intervention type: DEVICE
Group type: OTHER
Intervention: the modified pressure-reducing fixation protective nasal strip
Description: Materials Preparation consists of one foam dressing, one piece of 3M tape, and two pairs of scissors. 2. Manufacturing Procedure: step 1 Cut the foam dressing into two large rectangles and one little T-shape based on the patient's face shape and size as well as the width of the nasolabial fold. Attach these sections to the nasolabial fold region and both cheeks, respectively . Step 2: Based on the size of the oxygen cannula, set up small, medium, and large fixation patch models. Select the appropriate model according to the patient's condition and make the necessary cuts to properly secure the nasal prongs. Step 3: Check the tightness of the head strap, ensuring it is snug enough to fit one finger beneath it to avoid pressing on the skin around the ears. Ensure proper placement on the patient. See Figure 1 for detailed application.

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard care alone
Description: standard care plus a hydrocolloid dressing for protection
Study: NCT06719986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene HCl injection
Description: Nalmefene Hydrochloride injection 1.5 mg for intramuscular (IM) administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone HCl intranasal
Description: Naloxone 4 mg for intranasal (IN) administration
Study: NCT06720272

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: School nurse program
Description: The intervention consists in the introduction of a school-nurse program providing health care through education about rheumatic heart disease, assessment, intervention, and follow-up of group A beta-hemolytic streptococcal pharyngitis, and facilitation of secondary antibiotic prophylaxis for children with rheumatic heart disease.
Study: NCT06721182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REBOA
Description: endovascular balloon occlusion of the aorta
Study: NCT06720779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TRAK physio knee prosthesis protocol
Description: The exercise protocol designed for knee conditions is carried out through TRAK, the digital rehabilitation tool.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Knee conventional rehabilitation program
Description: Exercise protocol with the methodology of conventional clinical practice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knee conventional rehabilitation program
Description: Exercise protocol with the methodology of conventional clinical practice.
Study: NCT05262244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-IRDye800CW
Description: Bevacizumab-800CW is administered to the patient and angiography is performed before and directly after tracer administration and after 48-96 hours.
Study: NCT05277909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The expert assessment of shoulder impairments and individualised treatment plan
Description: The participant's diagnosis based on the history, symptoms and clinical findings will be used to guide the individualised treatment plan.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A minimal physiotherapeutic rehabilitation program delivered in a pamphlet
Description: This pamphlet contains a program with minimal exercise recommendations for the shoulder consisting of mobility, stretching, strength exercises and tissue treatment.
Study: NCT06149455

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Duration of antibiotics
Description: Patients will be randomized to a short (2 days) or long (7 days) of pre-operative antibiotics, the choice of agent will be dependent upon bacterial sensitivities if available which is standard of care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Duration of antibiotics
Description: Patients will be randomized to a short (2 days) or long (7 days) of pre-operative antibiotics, the choice of agent will be dependent upon bacterial sensitivities if available which is standard of care.
Study: NCT05798325

Intervention type: OTHER
Group type: OTHER
Intervention: 2MWT
Description: Two minutes walk tests.

Intervention type: OTHER
Group type: OTHER
Intervention: MFM32
Description: Motor Function Measurement (MFM) is a quantitative scale created to measure global motor functional abilities in a person with neuromuscular disease.

Intervention type: OTHER
Group type: OTHER
Intervention: MyoGrip
Description: The MyoGrip is a dynamometer for measuring grip strength.

Intervention type: OTHER
Group type: OTHER
Intervention: QOL-gNMD
Description: The Quality of Life in genetic Neuromuscular Disease questionnaire (QoL-gNMD) is a patient reported outcome measure (PROM) tool specifically designed for patients with a lowly progressive neuromuscular disease with genetically predominant muscular damage

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Spirometry
Description: Forced vital capacity (FVC), peak expiratory flow (PEF) and forced expiratory volume in 1 second (FEV1) will be measured in the hospital with the local hospital device (e.g. Vitalograph) under the supervision of the clinical evaluator, and at home with a portable device.
Study: NCT05098730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategy Training
Description: Strategy training is comprised of participant-selected activity based goals, self evaluation, global problem solving strategies, and therapist-delivered guided training. The strategy training therapist will guide participants using prompting questions, as well as work sheets that facilitate learning and aid the participants in implementing the process.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strategy Training
Description: Strategy training is comprised of participant-selected activity based goals, self evaluation, global problem solving strategies, and therapist-delivered guided training. The strategy training therapist will guide participants using prompting questions, as well as work sheets that facilitate learning and aid the participants in implementing the process.
Study: NCT05798325

Intervention type: DEVICE
Group type: OTHER
Intervention: Acceleromerty
Description: The Links sensor system is a measuring device and consists of the Links Pods and the Links Hub. The Links pods contain an accelerometer, gyroscope and magnetometer to measure position relative to a global reference frame.

Intervention type: OTHER
Group type: OTHER
Intervention: 10mWT
Description: 10 meters walking Test.

Intervention type: OTHER
Group type: OTHER
Intervention: PUL
Description: The Performance of the Upper Limb (PUL) is a functional scale specifically designed for assessing upper limb function in Duchenne muscular dystrophy.

Intervention type: OTHER
Group type: OTHER
Intervention: NSAA
Description: The North Star Ambulatory Assessment (NSAA) is a 17-item rating scale that is used to measure functional motor abilities in ambulant children with Duchenne Muscular Dystrophy.

Intervention type: OTHER
Group type: OTHER
Intervention: NSAD
Description: The NSAD was developed to measure motor performance in ambulant and non-ambulant subjects as part of the clinical outcome study of dysferlinopathy.

Intervention type: OTHER
Group type: OTHER
Intervention: TANS
Description: This scale is derived from the North Star Ambulatory Assessment and several items from the Egan Klassifikation Scale (EK2).

Intervention type: OTHER
Group type: OTHER
Intervention: MyoPinch
Description: The MyoPinch is a high-precision dynamometer that allows the evaluation of key pinch strength.

Intervention type: OTHER
Group type: OTHER
Intervention: MyoQuad
Description: The MyoQuad is a high-precision dynamometer that allows the evaluation of knee extension strength.

Intervention type: OTHER
Group type: OTHER
Intervention: ACTIVLIM
Description: Activity limitations, as measured by ACTIVLIM, is defined as the difficulties a patient may have in executing daily activities, whatever the strategies involved.

Intervention type: OTHER
Group type: OTHER
Intervention: PREM
Description: This questionnaire is made up of simple questions relating to the assessments and assessment tools that were used during the study.